Prognostic role of vascular endothelial growth factor in prostate cancer: A systematic review and meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 2, 2015, Pages 2289-2298

  Liu, Zhu Qing ^a   Fang, Jue Min ^a   Xiao, Yuan Yuan ^a   Zhao, Yu ^a   Cui, Ran ^a   Hu, Fei ^a   Xu, Qing ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Meta analysis; Prognosis; Prostate cancer; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; SYSTEMATIC REVIEW; TREATMENT FAILURE;

EID: 84926316838     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. [1] Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. [2] Holmboe ES and Concato J. Treatment decisions for localized prostate cancer: asking men what’s important. J Gen Intern Med 2000; 15: 694-701.
3. [3] George DJ and Kantoff PW. Prognostic indicators in hormone refractory prostate cancer. Urol Clin North Am 1999; 26: 303-310.
4. [4] Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT and Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-1451.
5. [5] Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
6. [6] Ferrara N, Gerber HP and LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
7. [7] Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
8. [8] Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36: 127-137.
9. [9] Hicklin DJ and Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
10. [10] Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D and Parker C. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008; 9: 342-351.
11. [11] George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW, Cancer and Leukemia Group B. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-1936.
12. [12] Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV and Pinski JK. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate 2010; 70: 1692-1700.
13. [13] Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA and Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
14. [14] Parmar MK, Torri V and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
15. [15] Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
16. [16] Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, Montorsi F, Slawin KM and Shariat SF. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 2009; 69: 886-894.
17. [17] Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA and Small EJ. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001; 61: 2533-2536.
18. [18] Fukuda H, Tsuchiya N, Narita S, Kumazawa T, Horikawa Y, Inoue T, Saito M, Yuasa T, Matsuura S, Satoh S, Ogawa O and Habuchi T. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncol Rep 2007; 18: 1155-1163.
19. [19] Green MM, Hiley CT, Shanks JH, Bottomley IC, West CM, Cowan RA and Stratford IJ. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 2007; 67: 84-90.
20. [20] Pan L, Baek S, Edmonds PR, Roach M 3rd, Wolkov H, Shah S, Pollack A, Hammond ME and Dicker AP. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiat Oncol 2013; 8: 100.
21. [21] Peyromaure M, Badoual C, Camparo P, Grabar S, Goulvestre C, Fulla Y, Vieillefond A, Mao K and Dinh-Xuan AT. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer. Oncol Rep 2007; 18: 145-149.
22. [22] Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM and Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004; 22: 1655-1663.
23. [23] Wang Q, Diao X, Sun J and Chen Z. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy. Urol Oncol 2013; 31: 312-317.
24. [24] West AF, O’Donnell M, Charlton RG, Neal DE and Leung HY. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer 2001; 85: 576-583.
25. [25] Weber DC, Tille JC, Combescure C, Egger JF, Laouiti M, Hammad K, Granger P, Rubbia-Brandt L and Miralbell R. The prognostic value of expression of HIF1alpha, EGFR and VEGF-A, in localized prostate cancer for intermediate-and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Radiat Oncol 2012; 7: 66.
26. [26] Mimeault M, Johansson SL and Batra SK. Pathobiological implications of the expression of EGFR, pAkt, NF-kappaB and MIC-1 in prostate cancer stem cells and their progenies. PLoS One 2012; 7: e31919.
27. [27] Ozden F, Saygin C, Uzunaslan D, Onal B, Durak H and Aki H. Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival. J Cancer Res Clin Oncol 2013; 139: 1373-1382.
28. [28] Liu ZQ, Chu L, Fang JM, Zhang X, Zhao HX, Chen YJ and Xu Q. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl 2014; 16: 467-471.
29. [29] Jiang X, Zhong W, Huang H, He H, Jiang F, Chen Y, Yue F, Zou J, Li X, He Y, You P, Yang W, Lai Y, Wang F and Liu L. Autophagy defects suggested by low levels of autophagy activator MAP1S and high levels of autophagy inhibitor LRPPRC predict poor prognosis of prostate cancer patients. Mol Carcinog 2014; [Epub ahead of print].
30. [30] Zeng XH, Ou ZL, Yu KD, Feng LY, Yin WJ, Li J, Shen ZZ and Shao ZM. Absence of multiple atypical chemokine binders (ACBs) and the presence of VEGF and MMP-9 predict axillary lymph node metastasis in early breast carcinomas. Med Oncol 2014; 31: 145.
31. [31] Wang K, Peng HL and Li LK. Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: a systematic review with meta-analysis. Asian Pac J Cancer Prev 2012; 13: 5665-5669.
32. [32] Senger DR, Connolly DT, Van de Water L, Feder J and Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990; 50: 1774-1778.
33. [33] Ferrara N and Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-858.
34. [34] Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J and Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-1312.
35. [35] Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
36. [36] Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM and Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470-1478.
37. [37] Shweiki D, Itin A, Soffer D and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
38. [38] Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG and Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995; 270: 12607-12613.
39. [39] Takahashi H and Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005; 109: 227-241.
40. [40] Rinck-Junior JA, Oliveira C, Lourenco GJ, Sagarra RA, Derchain SF, Segalla JG and Lima CS. Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer. J Cancer Res Clin Oncol 2015; 141: 69-73.
41. [41] Chen GQ, Luo JB, Wang GZ and Ding JE. Assessment of the associations between three VEGF polymorphisms and risk of prostate cancer. Tumour Biol 2014; 35: 1875-1879.
42. [42] Xu Y and Zhu S. Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: a meta-analysis. Tumour Biol 2014; 35: 1307-1311.